Orserdu Europeiska unionen - svenska - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Nolvadex 10 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nolvadex 10 mg tablett

astrazeneca ab - tamoxifencitrat - tablett - 10 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 15,2 mg aktiv substans - tamoxifen

Tamoxifen Orifarm 10 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tamoxifen orifarm 10 mg tablett

orifarm generics a/s - tamoxifencitrat - tablett - 10 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 15,2 mg aktiv substans - tamoxifen

Nolvadex 20 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nolvadex 20 mg tablett

astrazeneca ab - tamoxifencitrat - tablett - 20 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 30,4 mg aktiv substans - tamoxifen

Tamoxifen Mylan 20 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tamoxifen mylan 20 mg tablett

mylan ab - tamoxifencitrat - tablett - 20 mg - tamoxifencitrat 30,4 mg aktiv substans; mannitol hjälpämne - tamoxifen

Tamoxifen Sandoz 20 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tamoxifen sandoz 20 mg filmdragerad tablett

sandoz a/s - tamoxifencitrat - filmdragerad tablett - 20 mg - tamoxifencitrat 30,4 mg aktiv substans; laktosmonohydrat hjälpämne - tamoxifen

Tamoxifen Orifarm 20 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tamoxifen orifarm 20 mg tablett

orifarm generics a/s - tamoxifencitrat - tablett - 20 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 30,4 mg aktiv substans - tamoxifen

Tamoxifen Orifarm 30 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tamoxifen orifarm 30 mg tablett

orifarm generics a/s - tamoxifencitrat - tablett - 30 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 45,6 mg aktiv substans - tamoxifen

Fareston Europeiska unionen - svenska - EMA (European Medicines Agency)

fareston

orion corporation - toremifen - bröst-neoplasmer - endokrin terapi - första radhormonbehandling av hormonberoende metastatisk bröstcancer hos postmenopausala patienter. fareston rekommenderas inte för patienter med östrogen receptor-negativ tumörer.

Faslodex Europeiska unionen - svenska - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant - bröst-neoplasmer - endokrin terapi, anti-östrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausala kvinnor, kombinationsbehandling med palbociclib bör kombineras med en luteinizing hormone releasing hormone (gnrh) agonist.